Rogelio Machuca, MD
Family Medicine · Las Vegas, NVNPI 1245492966
Payments from drug & device makers
Across 213 payments — averaging $15,554 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.1M
- Genentech, Inc.$610K
- Romark Laboratories, LC$483K
- AstraZeneca$383K
- Pfizer$376K
- Eli Lilly$245K
- plus $73K from 23 others
Across 5 payments — averaging $18,924 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$81K
- Eli Lilly Export S.A. Puerto Rico Branch$14K
What the payments were for
- Consulting fees$7295%
- Travel & lodging$13,04483%
- Food & beverage$1,85912%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $1,142,422 |
| Genentech, Inc. | 41 | $609,510 |
| Romark Laboratories, LC | 5 | $483,436 |
| AstraZeneca | 18 | $383,006 |
| Pfizer | 47 | $376,196 |
| Eli Lilly | 1 | $245,176 |
| BD | 1 | $30,870 |
| Visby Medical, Inc. | 1 | $22,395 |
| Hoffmann-la Roche Limited | 4 | $11,738 |
| Sanofi Pasteur Inc. | 1 | $5,000 |
| Genentech USA, Inc. | 5 | $1,480 |
| Sanofi | 3 | $848 |
| Abbott | 14 | $333 |
| Amgen | 5 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $82 |
| Lilly USA, LLC | 5 | $78 |
| Mannkind Corporation | 2 | $61 |
| Astellas Pharma US Inc | 2 | $60 |
| Bayer | 2 | $50 |
| Novo Nordisk | 1 | $29 |
| Dexcom, Inc. | 1 | $26 |
| Almatica Pharma LLC | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xofluza$223
How this compares
$3,313,093 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 242 | $183,521 |
| MounjaroTirzepatide | 118 | $145,288 |
| OzempicSemaglutide | 83 | $84,393 |
| JardianceEmpagliflozin | 48 | $57,952 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $53,161 |
| FarxigaDapagliflozin Propanediol | 44 | $50,039 |
| JanuviaSitagliptin Phosphate | 36 | $46,120 |
| LinzessLinaclotide | 52 | $41,905 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 99 | $41,608 |
| RexultiBrexpiprazole | 22 | $32,942 |
| XareltoRivaroxaban | 29 | $28,444 |
| TrulicityDulaglutide | 22 | $22,984 |
| TradjentaLinagliptin | 19 | $22,535 |
| CreonLipase/Protease/Amylase | 15 | $22,512 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 495 | $20,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $376,196 | $183,521242 claims |
| Lilly USA, LLCMounjaro, Trulicity | $78 | $168,271140 claims |
| Novo NordiskOzempic | $29 | $84,39383 claims |
| AstraZenecaFarxiga, Brilinta | $383,006 | $69,71067 claims |
| AbbVieLinzess, Creon | $1,142,422 | $64,41767 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $11,35318 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $4,653489 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
- Robert KaplanLas Vegas$1.7M
- Sean SuLas Vegas$1.1M
- Naz WahabLas Vegas$735K
- Carmelo RilleraLas Vegas$531K
- Peter PhilanderLas Vegas$524K
- Jerry CadeLas Vegas$381K
- Dana ForteLas Vegas$169K
- Francisco MachucaLas Vegas$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.